Betamethasone Dipropionate Emollient Spray vs Halobetasol Propionate Lotion
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: Glucocorticoid receptor · full Psoriasis pipeline
Betamethasone Dipropionate Emollient Spray · Sernivo
Marketed by Primus Pharmaceuticals and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Halobetasol Propionate Lotion · Bryhali
Marketed by Bausch Health
NCT02514577 · Phase 3 · completed
The study was randomized, quadruple-blinded and vehicle-controlled, with 217 participants, and used a clinical Investigator's Global Assessment treatment-success endpoint at Week 8. The peer-reviewed report of the two Phase 3 trials states superiority over vehicle at Week 8 (36.5% (Study 1) vs vehicle, P<0.001), so the primary comparison was met.
Reported efficacy
Percentage of Participants With Treatment Success at Week 8: Percentage of Participants With Treatment Success at Week 8 (Week 8): IDP-122 Lotion 36.5% vs IDP-122 Vehicle Lotion 8.13% (met)
Result source: NCT02514577
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Betamethasone Dipropionate Emollient Spray | Halobetasol Propionate Lotion |
|---|---|---|
| PASI 75 | —Not reported | —Not reported |
| PASI 90 | —Not reported | —Not reported |
| PASI 100 | —Not reported | —Not reported |
| sPGA 0/1 | —Not reported | 36.5% vs 8.1%+28.4 vs placeboNCT025145779 other results
|
| DLQI, change | —Not reported | —Not reported |
PASI 75
- Betamethasone Dipropionate Emollient Spray
- —Not reported
- Halobetasol Propionate Lotion
- —Not reported
PASI 90
- Betamethasone Dipropionate Emollient Spray
- —Not reported
- Halobetasol Propionate Lotion
- —Not reported
PASI 100
- Betamethasone Dipropionate Emollient Spray
- —Not reported
- Halobetasol Propionate Lotion
- —Not reported
sPGA 0/1
- Betamethasone Dipropionate Emollient Spray
- —Not reported
- Halobetasol Propionate Lotion
- 36.5% vs 8.1%+28.4 vs placeboNCT02514577
9 other results
- 38.4% vs 12.0% NCT02515097
- 19.5% vs 6.7% NCT02514577
- 23.0% vs 9.3% NCT02515097
- 30.1% vs 7.9% NCT02514577
- 27.7% vs 4.3% NCT02515097
- 19.8% vs 2.8% NCT02514577
- 19.3% vs 0.2% NCT02515097
- 7.1% vs 0% NCT02514577
- 4.9% vs 0% NCT02515097
DLQI, change
- Betamethasone Dipropionate Emollient Spray
- —Not reported
- Halobetasol Propionate Lotion
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Betamethasone Dipropionate Emollient Spray: registry results are on file for Psoriasis, but their comparison mappings are not yet available.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Betamethasone Dipropionate Emollient Spray: 0 of 4 rows · Halobetasol Propionate Lotion: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Halobetasol Propionate Lotion |
|---|---|
| Dropout rate | 9.8%a NCT02514577 · Phase 3 · monotherapy · Psoriasis · phase 3 show 2 more results4.9% NCT02515097 · Phase 3 · monotherapy · Psoriasis · phase 3 0%0.05% lotion NCT01610596 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 0.7%a NCT02514577 · Phase 3 · monotherapy · Psoriasis · phase 3 show 2 more results1.4% NCT02515097 · Phase 3 · monotherapy · Psoriasis · phase 3 —0.05% lotion NCT01610596 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0.7%a NCT02514577 · Phase 3 · monotherapy · Psoriasis · phase 3 show 2 more results1.4% NCT02515097 · Phase 3 · monotherapy · Psoriasis · phase 3 0%0.05% lotion NCT01610596 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 0.05% lotiona application site pain 8.3% (placebo 8.3%) application site atrophy 5.6% (placebo 0%) application site discoloration 2.8% (placebo 0%) NCT01610596 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Halobetasol Propionate Lotion
show 9 more results
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Betamethasone Dipropionate Emollient Spray's landscape · Halobetasol Propionate Lotion's landscape